Oesophageal cancer: guideline history

No version history recorded yet for this cancer; the concordance rows below compare what each body says today.

Current positions

Only where bodies disagree1 of 1 settings


Oesophageal cancer · Adjuvant after chemoradiation, residual disease Nivolumab for one year after neoadjuvant chemoradiation and surgery with residual disease (CheckMate 577) Nivolumab CheckMate 577	Recommended Category 1 2021-05	Recommended I, A 2022	Recommended TA746 2021-11	·	Bodies agree

Other cancers

Acute myeloid leukaemia Bladder & urothelial cancer Cervical cancer Chronic lymphocytic leukaemia Colorectal cancer Diffuse large B-cell lymphoma Endometrial cancer Gastric & gastro-oesophageal junction cancer Hepatocellular carcinoma HER2-positive breast cancer HR-positive / HER2-negative breast cancer Melanoma Multiple myeloma Non-small-cell lung cancer Ovarian cancer Prostate cancer Renal cell carcinoma Triple-negative breast cancer (TNBC)

Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.